Source: Clearmind Medicine Inc.
  • Clearmind (CMND) has completed two R&D projects with leading scientists from multiple disciplines at the Hebrew University
  • This was part of a collaboration established with the university’s technology transfer company, Yissum
  • These projects yielded several promising drug candidates that Clearmind and Yissum are now advancing into novel patent applications
  • Clearmind is a psychedelic pharmaceutical biotech company
  • Clearmind Medicine Inc. (CMND) is up 2.74 per cent, trading at C$6.00 per share at 10:34 am ET

Clearmind (CMND) has completed two R&D projects with leading scientists from multiple disciplines at the Hebrew University.

This was part of a collaboration established with the university’s technology transfer company, Yissum. Yissum serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry.

The first project was led by Professor Dmitry Tsvelikhovsky, Professor Masha Niv and Professor Avi Priel. It was designed to investigate and discover innovative synthetic molecules based on known psychedelic chemical motifs. The project included the rational design of novel candidates and in-silico 3D docking studies on the 5HT2A serotonin receptor. It screened the candidates in an in-vitro platform to assess the receptor activation.

The second project was led by Professor Ahmad Masarwa, Professor Avi Priel, and Professor Rami Yaka. It was aimed to synthesize and evaluate the potential therapeutic effect of various chemical psychedelic analogues. The work included alterations of different regions of known molecules to potentially improve their binding capabilities to the 5HT2A receptor. The final stage of this project utilized an animal model to assess a possible increase in safety and efficacy.

These projects yielded several promising drug candidates that Clearmind and Yissum are now advancing into novel patent applications.

Clearmind is a psychedelic pharmaceutical biotech company. Its objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

Clearmind Medicine Inc. (CMND) is up 2.74 per cent, trading at C$6.00 per share at 10:34 am ET.


More From The Market Online

Top crypto stocks and ETFs to consider before the Bitcoin halving

Read about 10 of the highest-performing Bitcoin stocks and ETFs leading up to the cryptocurrency's April 2024 halving.

@ the Bell: Markets deeply divided amid Middle East flareup

Canada’s main stock index jumped on Friday, aiming to recoup some weekly losses, as investors shed caution around Middle East tensions.

Air Canada adds new in-flight sports channels before NHL playoffs

Air Canada (TSX:AC) adds three new live TV sports channels for its in-flight entertainment system just in time for the Stanley Cup Playoffs